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etter to the Editor
egression  of  vascular  calciﬁcation  in a  patient  with
alciphylaxis
egresión  de  calciﬁcaciones  vasculares  en  paciente  con  calciﬁlaxia
remained below 8 mg/dl, even with oral calcitriol supple-ear Sir,
e  describe a case of calciphylaxis with severe vascular
alciﬁcation (VC) in a patient with CKD, after initiation of treat-
ent for hyperparathyroidism. The patient made satisfactory
rogress with healing of the lesions, but mammography
evealed the return of the severe VC.
Calciphylaxis or calciﬁc uraemic arteriolopathy is a rare
ut signiﬁcant cause of morbidity and mortality in patients
ith chronic kidney failure (CKF). It consists of calciﬁcation of
he media layer in skin arterioles and produces very painful
esions that begin as subcutaneous nodules and progress to
schaemia and necrosis with formation of ulcers. It has been
inked to multiple factors, including hyperparathyroidism,
yperphosphataemia, use of vitamin D and calcium-chelating
gents, calciﬁcation-inhibitor deﬁciency, proteins C and S, and
se of oral anticoagulants, among other causes.1,2 VC is nec-
ssary but not sufﬁcient for the disease to manifest itself
linically.3
VC and its aetiological mechanism is a subject of great
nterest, as it is an independent factor associated with car-
iovascular mortality.4 Classically, it has been thought to be
n irreversible process, and the aim of nephrologists has been
o prevent it or at least slow down  its progression.
Our case was a 54-year-old woman with CKD secondary
o extracapillary glomerulonephritis with IgA deposits since
993. In April 2011, she was started on treatment with parical-
itol for hyperparathyroidism, being previously treated with
alcium carbonate for hyperphosphataemia. The creatinine
learance (Cr) was 20 ml/m and PTH > 2000 pg/ml.A year later, she was referred to the Advanced Chronic
idney Disease (ACKD) clinic, where calciphylaxis was sus-
ected due to the swollen and painful subcutaneous nodular
 Please cite this article as: Ruiz-Calero RM, Azevedo LM, Bayo MA, G
aciente con calciﬁlaxia. Nefrologia. 2016. http://dx.doi.org/10.1016/j.nepretibial lesions, which had developed into ulcers over the pre-
vious 5 months. Reviewing the patient’s mammogram from 3
months earlier, severe linear calciﬁcations could be seen in
both breasts which were not apparent on her previous mam-
mogram from 2008. Likewise she presented VC in other areas.
Kidney function had deteriorated (Cr 5.37, Cr clearance
with 24 h urine of 12.3 ml/m with PTH > 2000 pg/ml, calcium
[Ca] 9.2 mg/dl and phosphorus [P] 6.2 mg/dl) and it was decided
to start haemodialysis and discontinue paricalcitol and cal-
cium containing phosphate binders, She was started on
cinacalcet, sevelamer, sodium thiosulfate (ST), antibiotics and
opiates, and parathyroidectomy was scheduled. We  decided
not to take any biopsies due to the risk of infection of the
lesions.5
Presently there is no standard therapy for calciphy-
laxis. Parathyroidectomy may be indicated, but does not
always change the prognosis. Cinacalcet and bisphosphonates
have demonstrated beneﬁts, generally in combination with
other treatments. Hyperbaric oxygen can also improve tissue
hypoxia. ST has been associated with a rapid improvement in
the pain and resolution of the ischaemic ulcers thanks to its
antioxidant properties and it may also facilitate the elimina-
tion of vascular deposits of Ca.6
In our case, parathyroidectomy was performed a month
later, with the development of hungry bone syndrome and
the need for intravenous Ca and calcitriol supplementation
for hypocalcaemia. After 5 months of treatment with ST and
local wound care with silver patches, the ulcers healed (Fig. 1).
Since then, the patient’s Ca levels have persistentlyonzales B, Cubero JJ. Regresión de calciﬁcaciones vasculares en
froe.2016.10.008
mentation at low doses during the ﬁrst year after parathy-
roidectomy. Control of serum phosphate has been difﬁcult.
Three or more  chelating agents: sevelamer, lanthanum and
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Fig. 1 – Healing of calciphylaxis lesions after parathyroidectomy. At the beginning (A) and after 2 months (B) of treatment
with ST.
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1Fig. 2 – Right (above) and left (below) mamm
calcium acetate at full doses and, on occasion, aluminium
based chelating agents have been required, despite having
instructed the patient on how to take the chelating agents cor-
rectly and advise on foods with a better P/protein ratio. She has
been on online post-dilution HDF with a minimum duration of
4 h with good efﬁciency, with Kt/V and infusion volume within
current recommendations.
Initially, our aim was to prevent the death associated with
calciphylaxis, but also we  set a longer-term goal, which was
to prevent the progression of the VC. As can be seen on
the mammograms, the change was remarkable, with striking
regression of the calciﬁcations which is sustained at present
(Fig. 2).
We do not know which one of the various therapeutic
actions applied brought about the regression of the severe
VC presented at the start of haemodialysis. Correction of
the hyperparathyroidism and discontinuation of vitamin D
therapy, both of which could have been trigger factors,
were probably decisive in the initial management. Starting
2ams in 2011 (A), in 2013 (B) and in 2015 (C).
haemodialysis and the treatment with ST also played an
important role in the good calciphylaxis outcome. Control of
P and Ca over the longer term are factors that we  must not be
complacent about.
As a general conclusion, we would emphasise the multi-
factorial approach in the treatment of calciphylaxis, without
forgetting that, in terms of VC, the most important aspect is
prevention: control of mineral metabolism; judicious use of
vitamin D; and knowledge of precipitating factors in suscep-
tible patients.
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